Rare lephants
Screener

Cytek Biosciences, Inc.

CTKB ·Technology, Scientific & Technical Instruments, United States
Analysis › Moat Score

Moat Score — Cytek Biosciences, Inc.

Total Moat Score 11 / 30
Moat Factor Score Analysis
Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. 3 / 5 Proprietary Full Spectrum Profiling technology and related patents provide genuine, defensible technical differentiation versus legacy flow cytometry.
Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. 1 / 5 As a smaller player, Cytek lacks the manufacturing and procurement scale of giants like Danaher or Thermo Fisher.
Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. 2 / 5 Differentiated multiplexing capability supports premium pricing versus older platforms, but flat FY2025 revenue suggests pricing power is being tested by competitive response.
Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. 1 / 5 Minimal direct network effect, though a larger installed base modestly supports peer-reviewed publications and protocol sharing that reinforce adoption.
Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. 3 / 5 Once labs validate workflows and publish research on Cytek instruments, switching to a different platform requires costly revalidation, creating real installed-base stickiness.
Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. 1 / 5 The flow cytometry market comfortably supports multiple large, well-capitalized competitors, limiting any efficient-scale barrier for Cytek specifically.